S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
Is This The Collapse of Icahn Enterprises ?
BREAKING: Tiny biotech successfully treats blindness (Ad)
20 Best Healthcare Dividend Stocks to Invest in
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
BREAKING: Tiny biotech successfully treats blindness (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Elliott Management Says Goodyear Tire Worth At Least $21 a Share
BREAKING: Tiny biotech successfully treats blindness (Ad)
What Does the Airbnb Guidance Drop Say About Travel Demand?
Europe sees inflation drop to 6.1%, but real relief for consumers will take months
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
Is This The Collapse of Icahn Enterprises ?
BREAKING: Tiny biotech successfully treats blindness (Ad)
20 Best Healthcare Dividend Stocks to Invest in
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
BREAKING: Tiny biotech successfully treats blindness (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Elliott Management Says Goodyear Tire Worth At Least $21 a Share
BREAKING: Tiny biotech successfully treats blindness (Ad)
What Does the Airbnb Guidance Drop Say About Travel Demand?
Europe sees inflation drop to 6.1%, but real relief for consumers will take months
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
Is This The Collapse of Icahn Enterprises ?
BREAKING: Tiny biotech successfully treats blindness (Ad)
20 Best Healthcare Dividend Stocks to Invest in
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
BREAKING: Tiny biotech successfully treats blindness (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Elliott Management Says Goodyear Tire Worth At Least $21 a Share
BREAKING: Tiny biotech successfully treats blindness (Ad)
What Does the Airbnb Guidance Drop Say About Travel Demand?
Europe sees inflation drop to 6.1%, but real relief for consumers will take months
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
Is This The Collapse of Icahn Enterprises ?
BREAKING: Tiny biotech successfully treats blindness (Ad)
20 Best Healthcare Dividend Stocks to Invest in
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
BREAKING: Tiny biotech successfully treats blindness (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Elliott Management Says Goodyear Tire Worth At Least $21 a Share
BREAKING: Tiny biotech successfully treats blindness (Ad)
What Does the Airbnb Guidance Drop Say About Travel Demand?
Europe sees inflation drop to 6.1%, but real relief for consumers will take months
NYSE:EHAB

Enhabit (EHAB) Competitors

$11.94
+1.18 (+10.97%)
(As of 06/1/2023 ET)
Compare
Today's Range
$10.85
▼
$12.09
50-Day Range
$10.76
▼
$13.91
52-Week Range
$10.51
▼
$25.25
Volume
766,375 shs
Average Volume
551,541 shs
Market Capitalization
$598.19 million
P/E Ratio
15.31
Dividend Yield
N/A
Price Target
$16.13
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

EHAB vs. AVAH, AHCO, ADUS, ALDX, PAHC, LXRX, GHRS, BTAI, AUTL, and ZYME

Should you be buying Enhabit stock or one of its competitors? The main competitors of Enhabit include Aveanna Healthcare (AVAH), AdaptHealth (AHCO), Addus HomeCare (ADUS), Aldeyra Therapeutics (ALDX), Phibro Animal Health (PAHC), Lexicon Pharmaceuticals (LXRX), GH Research (GHRS), BioXcel Therapeutics (BTAI), Autolus Therapeutics (AUTL), and Zymeworks (ZYME). These companies are all part of the "medical" sector.

Enhabit vs.

Enhabit (NYSE:EHAB) and Aveanna Healthcare (NASDAQ:AVAH) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, community ranking, media sentiment and institutional ownership.

95.6% of Enhabit shares are owned by institutional investors. Comparatively, 91.7% of Aveanna Healthcare shares are owned by institutional investors. 1.9% of Enhabit shares are owned by company insiders. Comparatively, 6.9% of Aveanna Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Enhabit has a net margin of 3.64% compared to Aveanna Healthcare's net margin of -39.89%. Enhabit's return on equity of 6.59% beat Aveanna Healthcare's return on equity.

Company Net Margins Return on Equity Return on Assets
Enhabit 3.64% 6.59% 3.41%
Aveanna Healthcare -39.89% -19.78% -1.04%

Enhabit has higher earnings, but lower revenue than Aveanna Healthcare. Aveanna Healthcare is trading at a lower price-to-earnings ratio than Enhabit, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enhabit$1.06 billion0.56-$40.40 million$0.7815.31
Aveanna Healthcare$1.79 billion0.13-$662.03 million-$3.88-0.32

Enhabit presently has a consensus target price of $16.13, suggesting a potential upside of 35.05%. Aveanna Healthcare has a consensus target price of $4.84, suggesting a potential upside of 290.68%. Given Aveanna Healthcare's stronger consensus rating and higher possible upside, analysts plainly believe Aveanna Healthcare is more favorable than Enhabit.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enhabit
2 Sell rating(s)
5 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.00
Aveanna Healthcare
1 Sell rating(s)
5 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.22

In the previous week, Enhabit had 3 more articles in the media than Aveanna Healthcare. MarketBeat recorded 5 mentions for Enhabit and 2 mentions for Aveanna Healthcare. Enhabit's average media sentiment score of 0.49 beat Aveanna Healthcare's score of -1.00 indicating that Enhabit is being referred to more favorably in the media.

Company Overall Sentiment
Enhabit Neutral
Aveanna Healthcare Negative

Aveanna Healthcare received 21 more outperform votes than Enhabit when rated by MarketBeat users. Likewise, 40.35% of users gave Aveanna Healthcare an outperform vote while only 14.29% of users gave Enhabit an outperform vote.

CompanyUnderperformOutperform
EnhabitOutperform Votes
2
14.29%
Underperform Votes
12
85.71%
Aveanna HealthcareOutperform Votes
23
40.35%
Underperform Votes
34
59.65%

Summary

Enhabit beats Aveanna Healthcare on 10 of the 17 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EHAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EHAB vs. The Competition

Export to Excel
MetricEnhabitHome health care services IndustryMedical SectorNYSE Exchange
Market Cap$598.19M$2.74B$4.54B$14.56B
Dividend YieldN/A0.28%2.42%4.06%
P/E Ratio15.3136.71137.9820.11
Price / Sales0.561.263,638.928.98
Price / Cash2.4711.7591.0423.10
Price / Book0.783.115.159.21
Net Income-$40.40M-$9.76M$117.90M$902.99M
7 Day Performance2.58%2.11%3.20%1.00%
1 Month Performance-3.71%-4.11%3.13%-1.55%
1 Year PerformanceN/A-19.08%23.05%-9.05%

Enhabit Competitors List

Export to Excel
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AVAH
Aveanna Healthcare
1.6613 of 5 stars		$1.19
+21.4%		$2.34
+97.0%		-58.5%$224.74M$1.79B-0.313,700Gap Up
AHCO
AdaptHealth
3.2546 of 5 stars		$10.42
-0.6%		$18.92
+81.6%		-40.2%$1.40B$3.00B86.8310,900Positive News
ADUS
Addus HomeCare
2.7705 of 5 stars		$88.37
-0.5%		$112.75
+27.6%		+12.2%$1.43B$951.12M28.5133,182
ALDX
Aldeyra Therapeutics
1.6498 of 5 stars		$9.34
-0.3%		$18.00
+92.7%		+252.7%$547.14MN/A-8.9815
PAHC
Phibro Animal Health
2.7469 of 5 stars		$13.25
+0.4%		$18.00
+35.8%		-31.0%$536.63M$942.30M18.661,860Positive News
LXRX
Lexicon Pharmaceuticals
1.7926 of 5 stars		$2.90
-8.8%		$6.50
+124.1%		+54.9%$549.72M$140,000.00-4.6887Analyst Report
News Coverage
Gap Up
High Trading Volume
GHRS
GH Research
1.9717 of 5 stars		$10.90
-0.9%		$48.25
+342.7%		+20.4%$550.67MN/A-20.5714Short Interest ↑
Gap Up
High Trading Volume
BTAI
BioXcel Therapeutics
2.452 of 5 stars		$18.94
+0.4%		$50.29
+165.5%		+67.9%$552.29M$581,000.00-2.8689Short Interest ↓
AUTL
Autolus Therapeutics
2.4784 of 5 stars		$3.21
+13.4%		$8.20
+155.5%		+22.7%$555.57M$7.49M-2.31324
ZYME
Zymeworks
2.3545 of 5 stars		$8.18
-0.8%		$12.44
+52.1%		+21.6%$524.92M$446.14M3.16455

Related Companies and Tools

Related Companies:
Top 10 Stock Comparisons
This page (NYSE:EHAB) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -